Your browser doesn't support javascript.
loading
Development of Subcutaneous Panniculitis-Like T-cell Lymphoma After Immune Checkpoint Inhibitor Treatment.
Yu, Tommy Y; Gul, Zartash; Hunt, Alicia M; Williams, Michael J; Maley, Alexander M.
Afiliação
  • Yu TY; Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, USA.
  • Gul Z; Department of Oncology, Aurora St. Luke's Medical Center, Milwaukee, USA.
  • Hunt AM; Department of Pathology and Laboratory Medicine, Aurora St. Luke's Medical Center, Milwaukee, USA.
  • Williams MJ; Department of Pharmacy, Aurora St. Luke's Medical Center, Milwaukee, USA.
  • Maley AM; Department of Dermatology, Aurora St. Luke's Medical Center, Milwaukee, USA.
Cureus ; 16(8): e66974, 2024 Aug.
Article em En | MEDLINE | ID: mdl-39280467
ABSTRACT
Program death 1 (PD-1) inhibitors such as nivolumab are immune checkpoint inhibitors that have revolutionized the treatment of metastatic melanoma. Despite its success in treating melanoma, immune activation can lead to immune-related adverse effects, which are experienced by half of melanoma patients treated with PD-1 inhibitors. Despite the common frequency of immune-mediated adverse events, the development of a secondary lymphoma is exceedingly rare. We present the case of a 53-year-old woman diagnosed with stage IV metastatic melanoma, treated with nivolumab, who subsequently developed fatal subcutaneous panniculitis-like T-cell lymphoma (SPTCL).
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cureus Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cureus Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos